Edwards Lifesciences Corporation $EW Shares Sold by OLD National Bancorp IN

OLD National Bancorp IN decreased its stake in Edwards Lifesciences Corporation (NYSE:EW) by 69.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 58,421 shares of the medical research company’s stock after selling 132,226 shares during the period. OLD National Bancorp IN’s holdings in Edwards Lifesciences were worth $4,543,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its holdings in Edwards Lifesciences by 1.2% in the second quarter. Vanguard Group Inc. now owns 69,997,629 shares of the medical research company’s stock valued at $5,474,515,000 after buying an additional 798,801 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Edwards Lifesciences by 0.4% in the 2nd quarter. Geode Capital Management LLC now owns 12,722,416 shares of the medical research company’s stock worth $990,074,000 after acquiring an additional 45,555 shares during the period. Jennison Associates LLC increased its stake in Edwards Lifesciences by 15.7% in the 2nd quarter. Jennison Associates LLC now owns 11,670,991 shares of the medical research company’s stock valued at $912,788,000 after purchasing an additional 1,584,958 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its holdings in Edwards Lifesciences by 111.2% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock worth $714,006,000 after purchasing an additional 4,805,819 shares during the last quarter. Finally, Norges Bank acquired a new position in Edwards Lifesciences during the second quarter worth $580,640,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on EW. Jefferies Financial Group set a $98.00 target price on Edwards Lifesciences and gave the company a “buy” rating in a report on Wednesday, October 29th. Raymond James Financial raised shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price objective on the stock in a research note on Monday, November 3rd. JPMorgan Chase & Co. upgraded shares of Edwards Lifesciences from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $90.00 to $100.00 in a research report on Thursday, December 18th. Mizuho upped their price target on shares of Edwards Lifesciences from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Friday, October 31st. Finally, Citigroup reissued a “buy” rating and set a $101.00 price objective (up from $96.00) on shares of Edwards Lifesciences in a research note on Thursday, December 11th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $93.95.

Edwards Lifesciences Stock Performance

Shares of EW opened at $86.21 on Wednesday. The company has a market capitalization of $50.03 billion, a price-to-earnings ratio of 37.16, a PEG ratio of 3.89 and a beta of 0.97. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00. Edwards Lifesciences Corporation has a 1 year low of $65.94 and a 1 year high of $87.89. The company’s 50 day simple moving average is $83.06 and its 200 day simple moving average is $79.41.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. The company had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The business’s revenue for the quarter was up 14.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. On average, sell-side analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insiders Place Their Bets

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,700 shares of Edwards Lifesciences stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $84.47, for a total value of $650,419.00. Following the completion of the sale, the chief financial officer owned 39,898 shares in the company, valued at $3,370,184.06. The trade was a 16.18% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 11,386 shares of the stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $83.76, for a total transaction of $953,691.36. Following the transaction, the vice president owned 38,970 shares in the company, valued at approximately $3,264,127.20. The trade was a 22.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 45,465 shares of company stock valued at $3,804,610. Insiders own 0.34% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.